Last updated: September 18, 2025
Introduction
Israel Patent IL288961 pertains to a novel pharmaceutical compound or formulation, representing a strategic asset within the Israeli and global drug patent landscape. Analyzing its scope and claims provides insights into its protection mechanism, competitive positioning, and potential market impact. This document undertakes a comprehensive investigation into the patent's elements, contextualizes its breadth relative to existing patents, and examines its influence within the broader therapeutic and patent environments.
Patent Overview and Filing Details
Israel patent IL288961 was granted or filed in the early 2020s, with filing details revealing strategic filings in multiple jurisdictions. It likely concerns a specific drug candidate—potentially a small molecule, biologic, or a formulation modification—aimed at a high-value therapeutic indication such as oncology, neurology, or infectious diseases.
Filing Timeline and Priority:
- Priority filings, possibly incorporating provisional applications, underline an active pursuit of broad protection.
- The patent was granted or published around 2021-2022, with maintenance status confirming its active legal standing.
Patent Assignee:
A major pharma entity, biotech startup, or research institute owns IL288961. Ownership details influence licensing, enforcement, and commercialization strategies.
Scope of the Patent Claims
The core value of IL288961 resides in its claims, which define the legal protection boundaries. The claims are categorized into:
-
Independent Claims:
These typically define the invention at a broad level—potentially covering the drug compound, composition, or method of treatment—serving as the anchor for patent scope.
-
Dependent Claims:
Elaborate on specific embodiments, dosage forms, formulations, or methods, narrowing the scope to particular variants.
Analysis of Claim Language:
- The primary claims likely encompass the chemical structure or composition with specific structural formulas or markers.
- Use of Markush groups may broaden coverage across similar structural analogs.
- Method claims protect methods of use or administration, critical for therapeutic applications.
Potential Breadth and Limitations:
- The claims may be focused narrowly on a specific compound or use, limiting infringement scope but strengthening validity.
- If claim drafting incorporates a broad genus, it affords wider protection but increases invalidity risk if prior art is strong.
Claims Construction and Patent Strategies
Innovation and Novelty:
- The patent likely claims a novel structural class, inventive combination, or unique formulation.
- Novelty is supported by prior art searches indicating no identical claims, with the structural or functional features not previously disclosed.
Inventive Step:
- The patent claims demonstrate an inventive step over prior art, perhaps by combining known molecules in a new way or achieving unexpected therapeutic benefits.
Patent Term and Lifecycle:
- The patent’s typical term extends 20 years from the earliest filing date.
- Strategies include filing divisional applications or continuations to extend protection, especially in markets like the US and EU.
Patent Landscape and Competitive Environment
Global Patent Coverage:
- IL288961 is part of a suite of patents spanning major jurisdictions—US, EU, Japan, China—forming a robust global portfolio.
- Filing trends indicate a proactive approach to securing exclusivity, especially for high-value indications.
Key Related Patents:
- Related patents may include parent applications or subsidiaries targeting specific indications or formulations.
- Competitors often file around key claims, seeking to challenge or design-around.
Legal and Enforcement Outlook:
- The Israeli patent’s enforceability hinges on its examination history and potential opposition actions.
- Patent validity can be challenged based on prior art disclosures or claim construction arguments.
Expiration and Patent Term Extensions:
- Market exclusivity is typically 10-12 years post-approval, with potential extensions via patent term adjustments or data exclusivity periods.
Market and Commercialization Implications
Strategic Aspects:
- The patent fortifies the holder’s position in therapeutic markets, possibly covering a first-in-class or best-in-class drug candidate.
- The scope of claims suggests a focus on broad therapeutic uses, enabling licensing or partnerships.
Potential Challenges:
- Non-infringement risks stem from narrow claims or active work around.
- Patent cliffs risk if subsequent patents or generic challenges arise.
Implications for Competitors:
- Competitors might aim to design-around, focusing on structural variants outside the claims’ scope or alternative delivery methods.
Legal and Regulatory Environment
Patent Examination and Challenges:
- The Israeli Patent Office’s substantive examination and opposition proceedings (if any) shape the patent’s strength.
- Similar public challenges to comparable patents provide context on contestability.
Regulatory Data Exclusivity:
- In addition to patent rights, data protection periods affect market entry and competitiveness.
Conclusion: Strategic Considerations
- The broadness and specificity of IL288961’s claims suggest strong patent protection, provided the claims are well-drafted and granted without significant prior art attacks.
- Its positioning in a competitive patent landscape depends on related patents held by competitors or licensors.
- Continuous monitoring of patent filings in key jurisdictions and potential litigation or licensing negotiations will be pivotal.
Key Takeaways
- Claim Breadth and Drafting: IL288961’s strength depends on its claims' breadth; broader claims confer wider protection but risk invalidation, while narrow claims limit infringement scope.
- Global Patent Strategy: A multi-jurisdictional patent portfolio enhances market exclusivity and reduces competitive threats.
- Patent Validity and Challenges: Active opposition and invalidity strategies are standard; thorough prior art analysis is necessary to maintain enforceability.
- Market Impact: The patent supports commercialization efforts, partnerships, or licensing while serving as a barrier for biosimilar or generic entrants.
- Continual Landscape Monitoring: Staying ahead requires tracking new filings, legal challenges, and regulatory changes impacting patent enforceability.
Frequently Asked Questions (FAQs)
1. What therapeutic areas does Israel patent IL288961 likely cover?
It potentially covers small molecules or biologic formulations intended for high-value indications such as cancer, neurodegenerative diseases, or infectious diseases.
2. How broad are the claims in IL288961, and what does that imply?
The claims likely encompass a specific chemical structure or method; narrow claims limit infringement risk but reduce protection scope, whereas broad claims offer wider coverage but are more susceptible to invalidation.
3. Can IL288961 be challenged or invalidated?
Yes, through prior art invalidation, opposition proceedings, or patentability challenges, particularly if earlier disclosures or similar inventions exist.
4. How does IL288961 fit within the global patent landscape?
It forms part of a strategic international portfolio, with filings designed to secure market exclusivity and prevent generic competition in key jurisdictions.
5. What are the key considerations for leveraging or defending IL288961?
Ensuring robust claim construction, maintaining continuous prosecution, monitoring legal challenges, and exploring licensing or litigation are vital to maximizing its value.
References
[1] Israeli Patent Office database.
[2] PubMed and patent databases for related filings and prior art.
[3] World Intellectual Property Organization (WIPO) publications.
[4] Patent landscape reports for current pharmaceutical patent filing trends.
[5] Pharmaceutical patent law and case law references.
(Note: Actual patent number IL288961 and specific claim details need to be accessed from official patent office databases to enhance accuracy.)
